JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265295

Human VAC14 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

VAC14 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human VAC14 knockout HeLa cell line (AB265295)
  • Sanger seq

Unknown

Sanger Sequencing - Human VAC14 knockout HeLa cell line (AB265295)

Allele-2 : 1 bp insertion in exon 1.

Sanger Sequencing - Human VAC14 knockout HeLa cell line (AB265295)
  • Sanger seq

Unknown

Sanger Sequencing - Human VAC14 knockout HeLa cell line (AB265295)

Allele-1 : 1 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265295-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265295-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265295 Human VAC14 knockout HeLa cell line", "number":"AB265295-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265295-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265295-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265295 Human VAC14 knockout HeLa cell line", "number":"AB265295-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265295-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265295 Human VAC14 knockout HeLa cell line", "number":"AB265295-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265295-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265295 Human VAC14 knockout HeLa cell line", "number":"AB265295-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
VAC14
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VAC14 also known as ArPIKfyve is a regulatory protein with a molecular weight of roughly 100 kDa. It is expressed in various tissues but particularly notable in the brain. Mechanically VAC14 works with FIG4 and PIKFYVE in a complex that regulates the levels of phosphatidylinositol 35-bisphosphate (PI(35)P2) in cells. It interacts directly with PIKFYVE to control its kinase activity which is important for maintaining the balance of phosphoinositides.
Biological function summary

VAC14 takes an important role in phosphoinositide metabolism and is part of the PIKfyve complex which consists of PIKFYVE and FIG4. This complex regulates the synthesis of PI(35)P2 a lipid second messenger involved in various cellular processes. Through this regulation VAC14 influences membrane trafficking endosome-to-lysosome transport and lysosomal homeostasis. Proper functioning of VAC14 is essential for cellular integrity and response to environmental changes especially in neuronal cells.

Pathways

VAC14 involves itself in the phosphoinositide signaling pathway and the lysosomal pathway. This protein forms a module with PIKFYVE and FIG4 to control the production of PI(35)P2 which is important for endolysosomal dynamics. VAC14's activity influences autophagic flux and endosomal maturation processes integral to cellular homeostasis. The modulation of these pathways ensures proper intracellular processing and material degradation which is linked to cellular health and stress responses.

VAC14 has associations with Charcot-Marie-Tooth disease (CMT) and fibrotic lung disease. Mutations affecting VAC14 can lead to the malformation of neuronal axons and defects in both motor and sensory neurons in CMT. In these diseases VAC14 interacts with FIG4 where mutations in either protein can disrupt PI(35)P2 levels leading to neuropathy. Understanding the role of VAC14 in these contexts opens avenues for targeted therapeutic interventions in related neurological and fibrotic disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com